Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly results beat expectations and management raised its outlook, but the stocks muted, volatile reaction reflects a debate over whether strong AI demand can justify heavy capital spending, debt and rising interest costs. Bulls point to growth and contracted demand, while bears worry about cash burn and possible dilution.

Netlists third-quarter results and earnings call are driving attention, with traders focused on sharply improved profitability and margins, cash from the Samsung license, and expected recurring licensing revenue. Many see the results as a step toward more sustainable growth, while others question the steep quarter-over-quarter drop in product sales and await clearer guidance and updates on SK hynix.

NVIDIAs selloff is dominated by concerns over CEO Jensen Huangs admitted affair and allegations that the woman involved had ties to Chinese intelligence, prompting a board investigation and debate about disclosure, export-control risks, and his future as CEO. Traders are split between calling the drop an overreaction and buying the dip on confidence in AI-chip demand, and anticipating further losses if the investigation leads to Huangs departure.

The pending FDA decision on Capricors deramiocel treatment for Duchenne muscular dystrophy dominates discussion, with traders citing HOPE-3 results, an American Heart Association award and physician support as reasons for optimism. Others emphasize regulatory uncertainty and prior FDA concerns, while the earnings update is largely viewed as secondary; the debate is playing out amid sharp share-price volatility.

Rigettis Q3 results, particularly a revenue miss and weaker-than-expected outlook, have fueled selling and renewed concerns about commercialization, cash burn, and valuation. Some traders remain bullish on its quantum hardware progress and potential sector rebound, but the discussion is dominated by bearish reactions to the business results.

Amprius Q3 results are driving attention: revenue beat expectations and the company raised its 2026 outlook, but an EPS miss and negative EBITDA prompted a selloff. Traders are split between viewing the shortfall as minor relative to growth and guidance, and worrying about profitability and near-term weakness.

Fireflys third-quarter results are the main focus, with traders highlighting a revenue and adjusted-EPS beat, strong backlog, and the outlook while debating why the shares did not rise. Optimists point to the large AST SpaceMobile engine deal and future contract potential; skeptics remain concerned about cash burn and execution.

Nebius is drawing attention ahead of its Q3 report, with traders treating CoreWeaves strong results and raised outlook as a positive signal for AI-compute demand. Bulls expect Nebius to benefit, while skeptics question whether growth can be financed sustainably and capacity delivered without excessive debt or dilution.

LightPaths fiscal Q1 results are driving attention, with traders weighing revenue growth, a record backlog and strong order growth against concerns that results were merely in line and upbeat commentary may not translate quickly into execution. Reactions are split between long-term optimism about defense and optics demand and disappointment over weak after-hours trading.

Kuras Q3 update on KOMZIFTIs commercial launch is drawing attention, with growth in prescriptions outpacing new patient starts and encouraging some traders about repeat use and launch momentum. Others question the weak share-price reaction and point to competition in the menin-inhibitor market, including potential frontline AML rivals.